JOE Cross-Journal Searching
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (2004) 183, 445-454    DOI: 10.1677/joe.1.05620
© 2004 Society for Endocrinology

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schütt, M
Right arrow Articles by Klein, H H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schütt, M
Right arrow Articles by Klein, H H

Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells

M Schütt, J Zhou, M Meier and H H Klein1

Department of Internal Medicine I, University of Lübeck, Germany
1 Department of Internal Medicine, Ruhr-Universität Bochum, Berufsgenossenschaftliche Kliniken Bergmannsheil, Medizinische Klinik und Poliklinik, Bürkle de la Camp-Platz 1, D-44789 Bochum, Germany

(Requests for offprints should be addressed to H H Klein; Email: harald.klein{at}ruhr-uni-bochum.de)

The mechanism by which chronic treatment with HIV (human immunodeficiency virus)-1 protease inhibitors leads to a deterioration of glucose metabolism appears to involve insulin resistance, and may also involve impaired insulin secretion. Here we investigated the long-term effects of HIV-1 protease inhibitors on glucose-stimulated insulin secretion from beta cells and explored whether altered insulin secretion might be related to altered insulin signaling. INS-1 cells were incubated for 48 h with different concentrations of amprenavir, indinavir, nelfinavir, ritonavir or saquinavir, stimulated with 20 mM D-glucose, and insulin determined in the supernatant. To evaluate insulin signaling, cells were stimulated with 100 nM insulin for 2 min, and insulin-receptor substrate (IRS)-1, -2 and Akt phosphorylation determined. Incubation for 48 h with ritonavir, nelfinavir and saquinavir resulted in impaired glucose-induced insulin secretion at 2.5, 5 and 5 µM respectively, whereas amprenavir or indinavir had no effects even at 20 and 100 µM respectively. The impaired insulin secretion by ritonavir, nelfinavir and saquinavir was associated with decreased insulin-stimulated IRS-2 phosphorylation, and, for nelfinavir and saquinavir, with decreased insulin-stimulated IRS-1 and Thr308-Akt phosphorylation. No such effects on signaling were observed with amprenavir or indinavir. In conclusion, certain HIV-1 protease inhibitors, such as ritonavir, nelfinavir and saquinavir, not only induce peripheral insulin resistance, but also impair glucose-stimulated insulin secretion from beta cells. With respect to the long-term effect on beta-cell function there appear to be differences between the protease inhibitors that may be clinically relevant. Finally, these effects on insulin secretion after a 48 h incubation with protease inhibitor were associated with a reduction of the insulin-stimulated phosphorylation of insulin signaling parameters, particularly IRS-2, suggesting that protease inhibitor-induced alterations in the insulin signaling pathway may contribute to the impaired beta-cell function.




This article has been cited by other articles:


Home page
Diabetes CareHome page
S. Dagogo-Jack
HIV Therapy and Diabetes Risk
Diabetes Care, June 1, 2008; 31(6): 1267 - 1268.
[Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
K. Samaras
Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection
J. Antimicrob. Chemother., February 1, 2008; 61(2): 238 - 245.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. J. Gills, J. LoPiccolo, J. Tsurutani, R. H. Shoemaker, C. J.M. Best, M. S. Abu-Asab, J. Borojerdi, N. A. Warfel, E. R. Gardner, M. Danish, et al.
Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo
Clin. Cancer Res., September 1, 2007; 13(17): 5183 - 5194.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. C. Cuneo, T. Tu, L. Geng, A. Fu, D. E. Hallahan, and C. D. Willey
HIV Protease Inhibitors Enhance the Efficacy of Irradiation
Cancer Res., May 15, 2007; 67(10): 4886 - 4893.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Neye, M. Dufer, G. Drews, and P. Krippeit-Drews
HIV Protease Inhibitors: Suppression of Insulin Secretion by Inhibition of Voltage-Dependent K+ Currents and Anion Currents
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 106 - 112.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S. B. Haugaard, O. Andersen, S. Madsbad, C. Frosig, J. Iversen, J. O. Nielsen, and J. F.P. Wojtaszewski
Skeletal Muscle Insulin Signaling Defects Downstream of Phosphatidylinositol 3-Kinase at the Level of Akt Are Associated With Impaired Nonoxidative Glucose Disposal in HIV Lipodystrophy
Diabetes, December 1, 2005; 54(12): 3474 - 3483.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Society for Endocrinology.